文献速递妇科

剂量密集型与标准静脉化疗治疗卵巢癌的成本-效果分析:妇科肿瘤学组262号随机对照试验的经济学分析

Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
PubMed 文献 · Gynecol Oncol · 2017-02-10

基于GOG-262随机对照试验无贝伐珠单抗队列,采用三状态马尔可夫模型从医疗系统视角评估剂量密集型与标准静脉辅助化疗的成本-效果。剂量密集化疗的增量成本-效果比为每挽救一个无进展生命年8074.25美元(95%CI:7615.97-10207.16美元),99.8%的ICER估计值满足每PFLYS 50000美元的支付意愿阈值。结论认为剂量密集辅助化疗对晚期卵巢癌具有稳健的成本-效果。

要点

  • 基于GOG-262试验数据,剂量密集化疗较标准化疗的ICER为每PFLYS 8074.25美元(95%CI:7615.97-10207.16美元)。
  • 99.8%的ICER估计值满足每PFLYS 50000美元的支付意愿阈值,90%概率具有成本-效果的支付意愿值为每PFLYS 12000美元。
  • ICER估计仅对风险比敏感,但不超过每PFLYS 100000美元。

核心结论

  • 基于GOG-262结果,从医疗系统视角看,剂量密集辅助化疗对晚期卵巢癌具有稳健的成本-效果。

研究设计与样本

  • 采用三状态马尔可夫决策模型,从医疗系统视角,周期长度21天,时间跨度28个月,基于GOG-262随机对照试验无贝伐珠单抗队列计算每挽救一个无进展生命年的增量成本-效果比。
  • 化疗、并发症和监测成本来自Medicare或机构数据;无进展生存、中断和并发症发生率来自GOG-262;使用时间依赖转移概率和周期内校正;进行单因素和概率敏感性分析。

主要发现

  • 模型产生标准和剂量密集队列在28个月时的进展事件比例分别为84.3%和68.3%,与GOG-262试验中位随访时的比率匹配。
  • 标准化疗后中位无进展生存期为10.3个月,剂量密集治疗后的进展风险比为0.62。
  • 剂量密集化疗的ICER为每PFLYS 8074.25美元(95%CI:7615.97-10207.16美元)。
  • ICER估计仅对风险比估计敏感,但不超过每PFLYS 100000美元。
  • 99.8%的ICER估计值满足每PFLYS 50000美元的更严格支付意愿阈值;剂量密集治疗具有成本-效果的90%概率对应的支付意愿值为每PFLYS 12000美元。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the cost-effectiveness of dose-dense versus standard intravenous adjuvant chemotherapy for ovarian cancer using results from the no-bevacizumab cohort of the Gynecologic Oncology Group protocol 262 (GOG-262) randomized controlled trial, which reported a smaller absolute progression-free survival (PFS) benefit than the prior Japanese trial. METHODS: A three-state Markov decision model from a healthcare system perspective with a 21day cycle length and 28month time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per progression-free life-year saved (PFLYS) using results from GOG-262. Costs of chemotherapy, complications, and surveillance were from Medicare or institutional data. PFS, discontinuation, and complication rates were from GOG-262. Time-dependent transition probabilities and within-cycle corrections were used. One-way and probabilistic sensitivity analyses were performed. RESULTS: The model produces standard and dose-dense cohorts with 84.3% and 68.3% progression event proportions at 28months, matching GOG-262 rates at the trial's median follow-up. With a median PFS of 10.3months after standard chemotherapy and a hazard ratio for progression of 0.62 after dose-dense therapy, the ICER for dose-dense chemotherapy is $8074.25 (95% confidence interval: $7615.97-$10,207.16) per PFLYS. ICER estimates are sensitive only to the hazard ratio estimate but do not exceed $100,000 per PFLYS. 99.8% of ICER estimates met a more stringent willingness-to-pay of $50,000 per PFLYS. The willingness-to-pay value at which there is a 90% probability of dose-dense treatment being cost-effective is $12,000 per PFLYS. CONCLUSIONS: Dose-dense adjuvant chemotherapy is robustly cost-effective for advanced ovarian cancer from a healthcare system perspective based on results from GOG-262.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecol Oncol. 2017. PMID: 28196674. doi:10.1016/j.ygyno.2017.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。